Is Teleflex stock a Buy, Sell or Hold?
Teleflex stock has received a consensus rating of buy. The average rating score is and is based on 24 buy ratings, 15 hold ratings, and 0 sell ratings.What was the 52-week low for Teleflex stock?
The low in the last 52 weeks of Teleflex stock was 183.50. According to the current price, Teleflex is 128.52% away from the 52-week low.What was the 52-week high for Teleflex stock?
The high in the last 52 weeks of Teleflex stock was 356.37. According to the current price, Teleflex is 66.18% away from the 52-week high.What are analysts forecasts for Teleflex stock?
The 39 analysts offering price forecasts for Teleflex have a median target of 335.00, with a high estimate of 485.00 and a low estimate of 210.00. The median estimate represents a 70.40 difference from the last price of 235.84.Teleflex Stock Snapshot
235.98
Bid
2,500.00
Bid Size
235.99
Ask
1,400.00
Ask Size
3/17/2023
Date
4:15 PM
Time
259,974.00
Volume
232.22
Prev. Close
232.15
Open
10.59 B
Market Cap
46.94 M
Number of Shares
229.96
Day Low
236.91
Day High
235.84
183.50
52 Week Low
356.37
52 Week High
235.84
1.37
Dividend
0.61
Dividend Yield
19.01
P/E Ratio
99.71
Free Float in %
13.30
EPS 2023
92.48
Book Value per Share
18.66
Cash Flow per Share
Teleflex News More News
Teleflex Historical Prices
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Teleflex Analyst Data
Total Analysts: 39
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 210.00
Median: 335.00
Highest: 485.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Teleflex Analyst Opinions
- All
- Buy
- Hold
- Sell
| 02/24/23 | Raymond James Financial, Inc. | Maintained Buy | $259 | ||
| 02/24/23 | Needham & Company, LLC | Maintained Buy | $291 | ||
| 01/06/23 | Morgan Stanley | Maintained Hold | $280 | ||
| 12/28/22 | Stephens Inc. | Maintained Buy | $295 | ||
| 10/28/22 | RBC Capital Markets | Maintained Buy | $308 | ||
| 10/28/22 | Stephens Inc. | Maintained Buy | $280 | ||
| 10/28/22 | Raymond James Financial, Inc. | Maintained Buy | $231 | ||
| 10/28/22 | Wells Fargo & Co | Maintained Hold | $229 | ||
| 10/28/22 | JMP Securities LLC | Maintained Buy | $330 | ||
| 10/26/22 | Mizuho | Maintained Hold | $220 | ||
| 10/14/22 | Stephens Inc. | Maintained Buy | $305 | ||
| 10/12/22 | Jefferies & Company Inc. | Maintained Hold | $210 | ||
| 10/11/22 | Morgan Stanley | Maintained Hold | $236 | ||
| 08/01/22 | Raymond James Financial, Inc. | Maintained Buy | $266 | ||
| 07/29/22 | Morgan Stanley | Maintained Hold | $278 | ||
| 07/29/22 | JMP Securities LLC | Maintained Buy | $370 | ||
| 07/29/22 | Wells Fargo & Co | Downgraded to Hold | $248 | ||
| 07/15/22 | Morgan Stanley | Maintained Hold | $300 | ||
| 07/06/22 | Wolfe Research | Maintained Buy | |||
| 05/23/22 | Raymond James Financial, Inc. | Maintained Buy | $325 | ||
| 05/23/22 | RBC Capital Markets | Maintained Buy | $380 | ||
| 05/09/22 | Bank of America Merrill Lynch | Maintained Hold | $315 | ||
| 04/29/22 | Morgan Stanley | Maintained Hold | $343 | ||
| 04/29/22 | Raymond James Financial, Inc. | Maintained Buy | $355 | ||
| 04/29/22 | RBC Capital Markets | Maintained Buy | $390 | ||
| 04/29/22 | Needham & Company, LLC | Maintained Buy | $355 | ||
| 02/25/22 | Morgan Stanley | Maintained Hold | $378 | ||
| 02/23/22 | Raymond James Financial, Inc. | Maintained Buy | $370 | ||
| 01/31/22 | Needham & Company, LLC | Maintained Buy | $400 | ||
| 01/07/22 | Morgan Stanley | Downgraded to Hold | $383 | ||
| 01/04/22 | Piper Sandler | Downgraded to Hold | $325 | ||
| 12/13/21 | Wells Fargo & Co | Maintained Buy | $355 | ||
| 12/10/21 | RBC Capital Markets | Maintained Buy | $415 | ||
| 10/29/21 | Raymond James Financial, Inc. | Maintained Buy | $391 | ||
| 10/29/21 | Morgan Stanley | Maintained Buy | $431 | ||
| 10/29/21 | JMP Securities LLC | Maintained Buy | $430 | ||
| 07/30/21 | SVB Leerink | Maintained Hold | $415 | ||
| 07/19/21 | SVB Leerink | Downgraded to Hold | $410 | ||
| 04/30/21 | SVB Leerink | Maintained Buy | $485 | ||
| 04/30/21 | Morgan Stanley | Maintained Buy | $478 |
Teleflex Estimates* in USD
| 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|
| Revenue | 2,930 | 3,038 | 3,237 | 3,412 | 3,651 |
| Dividend | 1.37 | 1.38 | 1.36 | - | - |
| Dividend Yield (in %) | 0.61 % | 0.61 % | 0.60 % | - | - |
| EPS | 13.30 | 14.58 | 16.33 | 17.65 | 19.23 |
| P/E Ratio | 17.84 | 16.27 | 14.53 | 13.44 | 12.34 |
| EBIT | 774 | 840 | 927 | 994 | 1,090 |
| EBITDA | 849 | 913 | 1,005 | 994 | 1,089 |
| Net Profit | 633 | 697 | 782 | 853 | 933 |
| Net Profit Adjusted | 633 | 697 | 782 | 853 | 933 |
| Pre-Tax Profit | 707 | 786 | 882 | 958 | 1,051 |
| Net Profit (Adjusted) | 634 | 694 | - | - | - |
| EPS (Non-GAAP) ex. SOE | 13.30 | 14.58 | 16.33 | 17.65 | 19.23 |
| EPS (GAAP) | 9.68 | 11.07 | 12.71 | 14.14 | 16.12 |
| Gross Income | 1,737 | 1,839 | 1,987 | 2,107 | 2,276 |
| Cash Flow from Investing | -95 | -97 | -98 | -104 | -111 |
| Cash Flow from Operations | 558 | 650 | 851 | 948 | 1,025 |
| Cash Flow from Financing | -314 | -574 | -66 | -67 | -67 |
| Cash Flow per Share | 18.66 | 18.91 | - | - | - |
| Free Cash Flow | 501 | 612 | 728 | 803 | 884 |
| Free Cash Flow per Share | 14.20 | 15.86 | 17.48 | 19.38 | - |
| Book Value per Share | 92.48 | 101.03 | - | - | - |
| Net Debt | 754 | 234 | -1,049 | -1,908 | - |
| Research & Development Exp. | 123 | 128 | 139 | 150 | 169 |
| Capital Expenditure | 100 | 100 | 98 | 108 | - |
| Selling, General & Admin. Exp. | 839 | 868 | 921 | 963 | 1,016 |
| Shareholder’s Equity | 4,531 | 5,112 | 6,067 | 6,908 | 7,820 |
| Total Assets | 7,108 | 7,158 | 8,035 | 8,866 | 9,768 |
|
Previous Quarter ending 12/31/22 |
Current Quarter ending 03/31/23 |
Next Quarter ending 06/30/23 |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 12 | 14 | 14 | 14 | 14 |
| Average Estimate | 3.447 USD | 2.973 USD | 3.250 USD | 13.296 USD | 14.579 USD |
| Year Ago | 3.600 USD | 2.880 USD | 3.390 USD | 13.060 USD | 13.296 USD |
| Publish Date | 2/23/2023 | 4/27/2023 | 7/27/2023 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 11 | 13 | 13 | 14 | 14 |
| Average Estimate | 761 USD | 688 USD | 734 USD | 2,930 USD | 3,038 USD |
| Year Ago | 762 USD | 642 USD | 705 USD | 2,791 USD | 2,930 USD |
| Publish Date | 2/23/2023 | 4/27/2023 | 7/27/2023 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Teleflex Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Logue Daniel V. | 02/27/2023 | 1,139.00 | 10,590.89 | n/a | Buy | No |
| Winters James | 02/27/2023 | 912.00 | 2,392.00 | n/a | Buy | No |
| POWELL THOMAS E | 02/27/2023 | 2,357.00 | 14,384.00 | n/a | Buy | No |
| Kelly Liam | 02/27/2023 | 5,050.00 | 24,237.99 | n/a | Buy | No |
| Hicks Cameron P | 02/27/2023 | 906.00 | 9,045.49 | n/a | Buy | No |
| White Jay | 02/27/2023 | 1,347.00 | 4,592.00 | n/a | Buy | No |
| Deren John | 02/27/2023 | 414.00 | 1,595.00 | n/a | Buy | No |
| Logue Daniel V. | 02/24/2023 | 40.00 | 9,451.89 | 235.18 | Sell | No |
| Winters James | 02/24/2023 | 173.00 | 1,480.00 | 235.18 | Sell | No |
| POWELL THOMAS E | 02/24/2023 | 542.00 | 12,027.00 | 235.18 | Sell | No |
| Kelly Liam | 02/24/2023 | 1,025.00 | 19,187.99 | 235.18 | Sell | No |
| Hicks Cameron P | 02/24/2023 | 134.00 | 8,139.49 | 235.18 | Sell | No |
| White Jay | 02/24/2023 | 135.00 | 3,245.00 | 235.18 | Sell | No |
| Deren John | 02/24/2023 | 88.00 | 1,181.00 | 235.18 | Sell | No |
| Klasko Stephen K. M.D. | 01/26/2023 | 967.00 | 3,882.46 | 244.68 | Sell | No |
| Klasko Stephen K. M.D. | 01/26/2023 | 3,014.00 | 4,849.46 | 78.50 | Buy | No |
| Kelly Liam | 01/10/2023 | 2,173.00 | 20,192.29 | 259.48 | Sell | No |
| Kelly Liam | 01/10/2023 | 3,064.00 | 18,786.29 | 259.48 | Sell | No |
| Kelly Liam | 01/10/2023 | 2,173.00 | 19,634.29 | 259.48 | Sell | No |
| Kelly Liam | 01/10/2023 | 3,622.00 | 18,228.29 | 259.48 | Sell | No |
| Kelly Liam | 01/10/2023 | 3,579.00 | 22,365.29 | 82.26 | Buy | No |
| Kelly Liam | 01/10/2023 | 6,040.00 | 21,850.29 | 78.62 | Buy | No |
| Kelly Liam | 01/10/2023 | 3,579.00 | 21,807.29 | 82.26 | Buy | No |
| Kelly Liam | 01/10/2023 | 6,040.00 | 21,850.29 | 78.62 | Buy | No |
| Kelly Liam | 12/29/2022 | 3.00 | 15,810.29 | 251.00 | Sell | No |
Teleflex Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2022 | Teleflex Inc.Shs | 1.36 | 0.54 | USD |
| 2021 | Teleflex Inc.Shs | 1.36 | 0.41 | USD |
| 2020 | Teleflex Inc.Shs | 1.36 | 0.33 | USD |
| 2019 | Teleflex Inc.Shs | 1.36 | 0.36 | USD |
| 2018 | Teleflex Inc.Shs | 1.36 | 0.53 | USD |
| 2017 | Teleflex Inc.Shs | 1.36 | 0.55 | USD |
| 2016 | Teleflex Inc.Shs | 1.36 | 0.84 | USD |
| 2015 | Teleflex Inc.Shs | 1.36 | 1.03 | USD |
| 2014 | Teleflex Inc.Shs | 1.36 | 1.18 | USD |
| 2013 | Teleflex Inc.Shs | 1.36 | 1.45 | USD |
| 2012 | Teleflex Inc.Shs | 1.36 | 1.91 | USD |
| 2011 | Teleflex Inc.Shs | 1.36 | 2.22 | USD |
| 2010 | Teleflex Inc.Shs | 1.36 | 2.53 | USD |
| 2009 | Teleflex Inc.Shs | 1.36 | 2.52 | USD |
*Yield of the Respective Date
Teleflex Inc.Shs Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 2.973 USD | Q1 2023 Earnings Release | 04/27/2023 |
| Earnings Report | 3.250 USD | Q2 2023 Earnings Release | 07/27/2023 |
| Earnings Report | - | Q3 2023 Earnings Release | 10/26/2023 |
| Earnings Report | - | Q4 2023 Earnings Release | 02/22/2024 |
Teleflex Inc.Shs Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 3.520 USD | Q4 2022 Earnings Release | 02/23/2023 |
Teleflex Profile
Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers.
Moody’s Daily Credit Risk Score
Teleflex Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.72 |
| T. Rowe Price Investment Management, Inc. | 18.41 |
| Vanguard Group, Inc. (Subfiler) | 11.15 |
| Wellington Management Co. LLP | 6.59 |
| T Rowe Price Mid Cap Growth Fund | 5.54 |
| State Street Corp. | 4.87 |
| T Rowe Price Capital Appreciation Fund | 4.45 |
| T. Rowe Price Associates, Inc. (Investment Management) | 4.45 |
| Janus Henderson Investors US LLC | 4.30 |
| Atlanta Capital Management Co. LLC | 4.09 |
| BlackRock Fund Advisors | 3.18 |
| Vanguard Total Stock Market Index Fund | 3.08 |
| Janus Henderson Enterprise Fund | 3.04 |
| Eaton Vance Atlanta Capital SMID Cap Fund | 2.61 |
| T. Rowe Price Associates, Inc. (Investment Management) | 2.60 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Teleflex Management
| Name | Job |
|---|---|
| Liam J. Kelly | Chairman, President & Chief Executive Officer |
| John R. Deren | Chief Accounting Officer & Vice President |
| Howard Cyr | Chief Compliance Officer & Vice President |
| Thomas E. Powell | Chief Financial Officer & Executive Vice President |
| Timothy F. Duffy | Chief Information Officer & Vice President |
| Michelle Fox | Chief Medical Officer & Vice President |
| James Winters | Corporate VP-Manufacturing & Supply Chain |
| Neena M. Patil | Director |
| Candace H. Duncan | Independent Director |
| Stuart Allen Randle | Independent Director |
| Gretchen R. Haggerty | Independent Director |
| Stephen K. Klasko | Independent Director |
| John C. Heinmiller | Independent Director |
| Andrew A. Krakauer | Independent Director |
| George Babich | Lead Independent Director |
| Jay White | President & Vice President-Global Commercial |
| Daniel V. Logue | Secretary, Vice President & General Counsel |
| Justin McMurray | VP-Global Strategic Research & Development |
| Cameron P. Hicks | VP-Human Resources & Communications |
| Dominik Reterski | VP-Quality Assurance & Regulatory Affairs |
| Lawrence Keusch | Vice President & Strategy Development |
| Matt Tomkin | Vice President-Corporate Development |
| Michael Kryukov | Vice President-Global Tax |
| Marie Hendrixson | Vice President-Internal Audit |
| Karen T. Boylan | Vice President-Strategic Projects |
| Gregg W. Winter | Vice President-Taxes |